Dual anti-inflammatory mechanisms from KPV and BPC-157 provide powerful inflammation management for chronic and acute conditions
It also modulates nitric oxide pathways and growth factor expression, both of which play critical roles in how your body heals from injury, surgery, or chronic inflammation
The Food and Drug Administration is convening a panel of outside experts for a two-day meeting starting Thursday to make recommendations on whether compounding pharmacies should be allowed to make some of the most popular injectable peptides
As of April 22, 2026, it was removed from FDA Category 2, but the FDA's Pharmacy Compounding Advisory Committee will not consider it for the 503A bulks list until the July 23, 2026 meeting
As East Tennessees premier destination for functional medicine and hormone optimization, we combine cutting-edge peptide treatment with personalized care to help you achieve optimal wellness